Prurigo Nodularis Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Trevi Therapeutics, Galderma, Genentech, Incyte Crp., Vyne Therapeutics, Celgene

Posted on
by

Prurigo Nodularis Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Trevi Therapeutics, Galderma, Genentech, Incyte Crp., Vyne Therapeutics, Celgene
DelveInsight’s “Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Prurigo Nodularis, historical and forecasted epidemiology as well as the Prurigo Nodularis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

DelveInsight’s “Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Prurigo Nodularis, historical and forecasted epidemiology as well as the Prurigo Nodularis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Prurigo Nodularis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Prurigo Nodularis Market Forecast

 

Some of the key facts of the Prurigo Nodularis Market Report: 

  • The Prurigo Nodularis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In December 2022, In a joint statement, Regeneron Pharmaceuticals and Sanofi stated that the FDA will approve the drug injection in September 2022 for the treatment of adults with prurigo nodularis. The European Commission has expanded the marketing authorization for DUPIXENT (dupilumab) in the European Union to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.
  • The estimated prevalence of prurigo nodularis was 3.27 per 10,000 patients, according to Morgan et al. (2022). The prevalence of prurigo nodularis rose with age, ranging from 0-19 and 0-10 per 10,000 for male and female in the earliest age group (0-14 years), to 11-57 and 13-76 in the oldest age group (85 years), respectively. The prevalence was lower for males than for females (2.54 vs. 4.01 per 10,000)
  • According to Ständer et al., (2022) based on an anticipated population of 330 million, the predicted prevalence of 4.4 per 10,000 would translate to 144,000 cases of prurigo nodularis in the US
  • The National Organisation for Rare Disorders (2023) estimates that African Americans have a 3.4 times higher prevalence of PN. Patients with HIV infection tend to experience it more frequently
  • Key Prurigo Nodularis Companies: Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others
  • Key Prurigo Nodularis Therapies: Nalbuphine ER, Nemolizumab, Vixarelimab(KPL-716), Povorcitinib(INCB-54707), Ruxolitinib Cream, INCB054707, serlopitant, CC-10004, Pimecrolimus, Abrocitinib, Dupilumab SAR231893, and others
  • The Prurigo Nodularis epidemiology based on gender analyzed that females are affected more as compared to males, in the case of Prurigo Nodularis
  • The Prurigo Nodularis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Prurigo Nodularis pipeline products will significantly revolutionize the Prurigo Nodularis market dynamics.

 

Prurigo Nodularis Overview

An extremely itchy, chronic inflammatory skin disorder known as prurigo nodularis (PN) is characterised by localised or generalised hyperkeratotic papules and nodules that are typically distributed symmetrically. In individuals with chronic prurigo (CP), which can have a variety of aetiologies, including dermatological, systemic, infectious, and mental, PN often comes with long-lasting itch.

 

Get a Free sample for the Prurigo Nodularis Market Report 

https://www.delveinsight.com/report-store/prurigo-nodularis-market

 

Prurigo Nodularis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Prurigo Nodularis Epidemiology Segmentation:

The Prurigo Nodularis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Prurigo Nodularis
  • Prevalent Cases of Prurigo Nodularis by severity
  • Gender-specific Prevalence of Prurigo Nodularis
  • Diagnosed Cases of Episodic and Chronic Prurigo Nodularis

 

Download the report to understand which factors are driving Prurigo Nodularis epidemiology trends @ Prurigo Nodularis Epidemiology Forecast

 

Prurigo Nodularis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prurigo Nodularis market or expected to get launched during the study period. The analysis covers Prurigo Nodularis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Prurigo Nodularis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Prurigo Nodularis Therapies and Key Companies

  • Nalbuphine ER: Trevi Therapeutics
  • Nemolizumab: Galderma
  • Vixarelimab(KPL-716): Genentech
  • Povorcitinib(INCB-54707): Incyte Corporation
  • Ruxolitinib Cream: Incyte Corporation
  • INCB054707: Incyte Corporation
  • serlopitant: Vyne Therapeutics Inc.
  • CC-10004: Celgene Corporation
  • Pimecrolimus: Novartis
  • Abrocitinib: Pfizer
  • Dupilumab SAR231893: Regeneron Pharma

 

Discover more about therapies set to grab major Prurigo Nodularis market share @ Prurigo Nodularis Treatment Market

 

Prurigo Nodularis Market Strengths

  • Novel drug formulations are unlocking the new market outlook and the potential to improve the QoL of patients suffering from the serious symptoms associated with chronic neurologically mediated conditions for which there are few, if any, treatment options.
  • Vixarelimab’s dual mechanism offers potential pruritus relief and nodule improvement in prurigo nodularis.

 

Prurigo Nodularis Market Opportunities

  • Prurigo Nodularis overlap with those of several common skin diseases, due to which the differential diagnosis is needed to avoid misdiagnosis.
  • Due to one approved drug in the market, there is a huge opportunity for the companies who are coming up with novel emerging therapies.

 

Scope of the Prurigo Nodularis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Prurigo Nodularis Companies: Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others
  • Key Prurigo Nodularis Therapies: Nalbuphine ER, Nemolizumab, Vixarelimab(KPL-716), Povorcitinib(INCB-54707), Ruxolitinib Cream, INCB054707, serlopitant, CC-10004, Pimecrolimus, Abrocitinib, Dupilumab SAR231893, and others
  • Prurigo Nodularis Therapeutic Assessment: Prurigo Nodularis current marketed and Prurigo Nodularis emerging therapies
  • Prurigo Nodularis Market Dynamics: Prurigo Nodularis market drivers and Prurigo Nodularis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Prurigo Nodularis Unmet Needs, KOL’s views, Analyst’s views, Prurigo Nodularis Market Access and Reimbursement 

 

To know more about Prurigo Nodularis companies working in the treatment market, visit @ Prurigo Nodularis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Prurigo Nodularis Market Report Introduction

2. Executive Summary for Prurigo Nodularis

3. SWOT analysis of Prurigo Nodularis

4. Prurigo Nodularis Patient Share (%) Overview at a Glance

5. Prurigo Nodularis Market Overview at a Glance

6. Prurigo Nodularis Disease Background and Overview

7. Prurigo Nodularis Epidemiology and Patient Population

8. Country-Specific Patient Population of Prurigo Nodularis 

9. Prurigo Nodularis Current Treatment and Medical Practices

10. Prurigo Nodularis Unmet Needs

11. Prurigo Nodularis Emerging Therapies

12. Prurigo Nodularis Market Outlook

13. Country-Wise Prurigo Nodularis Market Analysis (2019–2032)

14. Prurigo Nodularis Market Access and Reimbursement of Therapies

15. Prurigo Nodularis Market Drivers

16. Prurigo Nodularis Market Barriers

17.  Prurigo Nodularis Appendix

18. Prurigo Nodularis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services